South America Amniotic Products Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type, Application, and End User

The SAM amniotic products market is expected to grow from US$ 71.16 million in 2022 to US$ 111.62 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2022 to 2028.

According to a 2018 retrospective examination of Medicare users, 8.2 million persons suffered wounds that were infected or not. The cost of acute and chronic wound treatments was estimated to cost between US$ 28.1 billion and US$ 96.8 billion by Medicare. Surgical wounds were the most expensive, followed by diabetic foot ulcers, with outpatient wound care costs higher than inpatient wound care. Traumatic wounds are a significant clinical, social, and economic burden because of the rising healthcare expenditures, an aging population, identification of difficult-to-treat infection risks such as biofilms, and the global hazard of diabetes and obesity. Traumatic wounds are those that have not proceeded through the normal healing process and have been open for longer than a month. Traumatic wounds have a variety of causes, all of which place a strain on the healthcare system. Diabetic and obese patients are at a higher risk of getting chronic wounds. Most persons who have a long-term open wound also have additional serious health problems. Comorbidity refers to the existence of multiple chronic diseases at the same time. Comorbidities complicate chronic wounds, making it difficult to follow chronic wounds as a disease in and of itself. In comparison to the overall burden of chronic wounds as a health care concern, research funding dedicated to studying chronic wounds is disproportionately low. Wound healing using amniotic membrane grafts has some therapeutic potential. Early use of an amniotic membrane for ulcers, burns, and cutaneous injuries proved therapeutic. Therefore, an increasing number of traumatic wounds is boosting the amniotic product market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM amniotic products market . The SAM amniotic products market is expected to grow at a good CAGR during the forecast period.

SAM Amniotic Products Market Segmentation

The SAM amniotic products market is bifurcated based on type, application, end user and country.

• Based on type, the market is segmented into amniotic membranes, and amniotic suspensions. The amniotic membranes segment dominated the market in 2022 and is expected to be fastest growing during forecast period.
• Based on application, the market is segmented into wound care, orthopedics, ophthalmology, and other applications. The wound care segment dominated the market in 2022 and orthopedics segment is expected to be fastest growing during forecast period.
• Based on end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market in 2022 and ambulatory surgical centers segment is expected to be fastest growing during forecast period.
• Based on country, the SAM amniotic products market is segmented into the Brazil, Argentina, and Rest of SAM.

Integra LifeSciences; Katena Products. Inc.; MiMedx; NuVision Biotherapies Ltd; Organogenesis, Inc.; Sanuwave and Sanuwave Health, Inc.; Smith & Nephew; and Stryker are among the leading companies in the SAM amniotic products market.